51116-01-9
51116-01-9
Chemical Structure
8-Bromo-cGMP sodium
- CAS No.: 51116-01-9
- Formula:C10H10BrN5NaO7P
- Molecular Weight:446.08
IUPAC Name: sodium (4aR,6R,7R,7aS)-6-(2-amino-8-bromo-6-oxo-3,6-dihydro-9H-purin-9-yl)-7-hydroxytetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinin-2-olate 2-oxide
InChIKey: ZJRFCXHKYQVNFK-YEOHUATISA-M
SMILES: O=C1C2=C(N([C@H]3[C@H](O)[C@@](OP(OC4)(O[Na])=O)([H])[C@]4([H])O3)C(Br)=N2)NC(N)=N1
Biological Activity: 8-Bromo-cGMP sodium, a membrane-permeable analogue of cGMP, is a PKG (protein kinase G) activator. 8-Bromo-cGMP sodium significantly inhibits Ca2+ macroscopic currents and impairs insulin release stimulated with high K+[1]. 8-Bromo-cGMP sodium has antinociceptive effects and results in vasodilator responses[2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
8-Bromo-cGMP sodium | 99.89% | 8-Bromo-cGMP sodium, a membrane-permeable analogue of cGMP, is a PKG (protein kinase G) activator. 8-Bromo-cGMP sodium significantly inhibits Ca2+ macroscopic currents and impairs insulin release stimulated with high K+. 8-Bromo-cGMP sodium has antinociceptive effects and results in vasodilator responses. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
8-Bromo-cGMP sodium (Standard) | ≥98% | 8-Bromo-cGMP (sodium) (Standard) is the analytical standard of 8-Bromo-cGMP (sodium) (HY-101379A). This product is intended for research and analytical applications. 8-Bromo-cGMP sodium, a membrane-permeable analogue of cGMP, is a PKG (protein kinase G) activator. 8-Bromo-cGMP sodium significantly inhibits Ca2+ macroscopic currents and impairs insulin release stimulated with high K+. 8-Bromo-cGMP sodium has antinociceptive effects and results in vasodilator responses. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
8-Bromo-cAMP sodium salt | 99.91% | 8-Bromo-cAMP sodium (8-Br-Camp) sodium salt, a cyclic AMP analog, is an activator of cyclic AMP-dependent protein kinase (PKA). 8-Bromo-cAMP sodium salt has anti-proliferative and apoptotic effects against cancer cells. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
8-Br-cAMP-AM | 8-Br-cAMP-AM is a cyclic adenosine monophosphate (cAMP) analog that activates two major signal transduction pathways in the heart by mimicking the effects of cAMP: protein kinase A (PKA) and guanosine nucleotide exchange factor (Epac), which is directly activated by cAMP. 8-Br-cAMP-AM can be used to study cardiac ischemia and reperfusion injury. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
8-Br-cGMP-AM | 8-Br-cGMP-AM is a cGMP analog. 8-Br-cGMP-AM is a membrane-permeable, bioactivatable acetoxymethyl ester designed to avoid rapid cGMP turnover. 8-Br-cGMP-AM mediates the phosphorylation of CRP4. 8-Br-cGMP-AM has anticancer activity against leukemia. 8-Br-cGMP-AM can be used for research on acute myeloid leukemia. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
8-Nitro-cGMP | 8-Nitro-cGMP is an electrophilic second messenger of redox signaling that can form a protein-S-cGMP adduct in s-guanylation process. 8-Nitro-cGMP is an autophagy inducer. 8-Nitro-cGMP promotes RANKL-induced osteoclast differentiation from macrophages. 8-Nitro-cGMP has vasodilator effect, and ameliorates the vascular endothelial dysfunction in diabetic mice. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Rp-8-Br-cGMPS sodium | 99.7% | Rp-8-Br-cGMPS (Rp-8-bromo-Cyclic GMPS) sodium salt is a potent Ca2+-ATPase activator. Rp-8-Br-cGMPS is also an agonist of the rod CNG channel and an inhibitor of PKG. Rp-8-Br-cGMPS sodium salt mediates cytosolic Ca2+ reduction by activating Ca2+-ATPase and subsequently removing Ca2+ from the cell. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Rp-8-Br-cGMPS | Rp-8-Br-cGMPS (Rp-8-bromo-Cyclic GMPS) sodium salt is a potent Ca2+-ATPase activator. Rp-8-Br-cGMPS is also an agonist of the rod CNG channel and an inhibitor of PKG. Rp-8-Br-cGMPS sodium salt mediates cytosolic Ca2+ reduction by activating Ca2+-ATPase and subsequently removing Ca2+ from the cell. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
8-Pcpt-cGMP sodium | 99.0% | 8-Pcpt-cGMP sodium is the sodium salt form of 8-Pcpt-cGMP (HY-137016). 8-Pcpt-cGMP sodium is an agonist for cyclic nucleotide-gated (CNG) channel with an EC50 of 0.5 μM. 8-Pcpt-cGMP sodium exhibits good membrane permeability. 8-Pcpt-cGMP sodium can be used in studies about the function of CNG channels in visual signal transduction and olfactory transduction. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Sp-cGMPS | Sp-cGMPS is an activator of cGMP-dependent protein kinases (PKGs). Sp-cGMPS can be used in cardiovascular disease-related research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Sp-8-Br-cGMPS | Sp-8-Br-cGMPS is an analog of cGMP. Sp-8-Br-cGMPS is an agonist for cGMP-gated cation channels (CNG channels), with an EC50 of 106.5 μM. Sp-8-Br-cGMPS induces the currents, without the ability to stabilize the channel open state as a full agonist. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
8-Bromo-3’-deoxy-3’-fluoroguanosine | 8-Bromo-3’-deoxy-3’-fluoroguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Sarkar O , et al. Nitric oxide attenuates overexpression of Giα proteins in vascular smooth muscle cells from SHR: Role of ROS and ROS-mediated signaling. PLoS One. 2017 Jul 10;12(7):e0179301. [Content Brief]
- [2]. Tegeder I , et al. Dual effects of spinally delivered 8-bromo-cyclic guanosine mono-phosphate (8-bromo-cGMP) in formalin-induced nociception in rats. Neurosci Lett. 2002 Oct 31;332(2):146-50. [Content Brief]
